CASE Plots for the Chemotype‐Based Activity and Selectivity Analysis: A CASE Study of Cyclooxygenase Inhibitors

Structure–activity characterization of molecular databases plays a central role in drug discovery. However, the characterization of large databases containing structurally diverse molecules with several end‐points represents a major challenge. For this purpose, the use of chemoinformatic methods plays an important role to elucidate structure–activity relationships. Herein, a general methodology, namely Chemotype Activity and Selectivity Enrichment plots, is presented. Chemotype Activity and Selectivity Enrichment plots provide graphical information concerning the activity and selectivity patterns of particular chemotypes contained in structurally diverse databases. As a case study, we analyzed a set of 658 compounds screened against cyclooxygenase‐1 and cyclooxygenase‐2. Chemotype Activity and Selectivity Enrichment plots analysis highlighted chemotypes enriched with active and selective molecules against cyclooxygenase‐2; all this in a simple 2D graphical representation. Additionally, the most active and selective chemotypes detected in Chemotype Activity and Selectivity Enrichment plots were analyzed separately using the previously reported dual activity–difference maps. These findings indicate that Chemotype Activity and Selectivity Enrichment plots and dual activity–difference maps are complementary chemoinformatic tools to explore the structure–activity relationships of structurally diverse databases screened against two biological end‐points.

[1]  Claus Schneider,et al.  Cyclooxygenases and lipoxygenases in cancer , 2011, Cancer and Metastasis Reviews.

[2]  Jaime Pérez-Villanueva,et al.  Activity landscape modeling of PPAR ligands with dual-activity difference maps. , 2012, Bioorganic & medicinal chemistry.

[3]  H. Kubinyi QSAR and 3D QSAR in drug design Part 1: methodology , 1997 .

[4]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[5]  Mathias Wawer,et al.  Navigating structure-activity landscapes. , 2009, Drug discovery today.

[6]  Xi Chen,et al.  The Binding Database: data management and interface design , 2002, Bioinform..

[7]  José L. Medina-Franco,et al.  Structure–activity relationships of benzimidazole derivatives as antiparasitic agents: Dual activity-difference (DAD) maps , 2011 .

[8]  Yoo Jakyung,et al.  Chemoinformatic Approaches for Inhibitors of DNA Methyltransferases: Comprehensive Characterization of Screening Libraries , 2011 .

[9]  Mark Johnson,et al.  Using Molecular Equivalence Numbers To Visually Explore Structural Features that Distinguish Chemical Libraries , 2002, J. Chem. Inf. Comput. Sci..

[10]  W. Kiefer,et al.  Cyclooxygenase inhibitors--current status and future prospects. , 2001, European journal of medicinal chemistry.

[11]  X Chen,et al.  The binding database: overview and user's guide. , 2001, Biopolymers.

[12]  J. Bajorath,et al.  Comparison of two- and three-dimensional activity landscape representations for different compound data sets , 2011 .

[13]  Gerald M. Maggiora,et al.  Hierarchical Strategy for Identifying Active Chemotype Classes in Compound Databases , 2006, Chemical biology & drug design.

[14]  Austin B. Yongye,et al.  Multitarget Structure-Activity Relationships Characterized by Activity-Difference Maps and Consensus Similarity Measure , 2011, J. Chem. Inf. Model..

[15]  Ansgar Schuffenhauer,et al.  Rule‐Based Classification of Chemical Structures by Scaffold , 2011, Molecular informatics.

[16]  J. Medina-Franco,et al.  Natural products as DNA methyltransferase inhibitors: a computer-aided discovery approach , 2010, Molecular Diversity.

[17]  I. Chessell,et al.  The role of the cylooxygenase pathway in nociception and pain. , 2006, Seminars in cell & developmental biology.

[18]  L. Ghibelli,et al.  The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies , 2010, International journal of cell biology.

[19]  Mark Johnson,et al.  Algorithm for Naming Molecular Equivalence Classes Represented by Labeled Pseudographs , 2001, J. Chem. Inf. Comput. Sci..

[20]  H. Kubinyi QSAR and 3D QSAR in drug design Part 2: applications and problems , 1997 .

[21]  F. Ooms,et al.  Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry. , 2000, Current medicinal chemistry.

[22]  Rajarshi Guha,et al.  Chemoinformatic Analysis of Combinatorial Libraries, Drugs, Natural Products, and Molecular Libraries Small Molecule Repository , 2009, J. Chem. Inf. Model..